Acelrx Pharmaceuticals, Inc.
For patients with acute pain, a slip of the tongue could be a useful thing. AcelRx is developing the Sufentanil NanoTab PCA System, which administers pain medication sublingually, or under the tongue. Designed for patients with post-operative pain, the system administers measured doses of the opioid sufentanil in the form of tiny tablets, which quickly dissolve and are absorbed into the body through the lining under the tongue. Currently in late-stage of development, its NanoTab system is also being developed to treat cancer-related pain or provide sedation and pain relief to patients having procedures at doctors' offices. Founded in 2005, AcelRx went public in 2011 through a $40 million IPO.
Parent Topics

About Privacy Terms faq

2022 CareerAnswers